Independent Director of Eupraxia Pharmaceuticals Picks Up 13% More Stock [Yahoo! Finance]
Eupraxia Pharmaceuticals Inc. (EPRX)
Company Research
Source: Yahoo! Finance
TSE:EPRX ) will no doubt be intrigued by the recent purchase of shares by Joseph Freedman, Independent Director of the company, who spent a stonking CA$1.8m on stock at an average price of CA$7.64. Aside from being a solid chunk in its own right, the deft move also saw their holding increase by some 13%. This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. The Last 12 Months Of Insider Transactions At Eupraxia Pharmaceuticals Notably, that recent purchase by Joseph Freedman is the biggest insider purchase of Eupraxia Pharmaceuticals shares that we've seen in the last year. So it's clear an insider wanted to buy, at around the current price, which is CA$7.99. That means they have been optimistic about the company in the past, though they may have changed their mind. We do always like to see insider buying, but it is worth noting if those purchases were made at well below today's share price, as the discount to value may
Show less
Read more
Impact Snapshot
Event Time:
EPRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EPRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EPRX alerts
High impacting Eupraxia Pharmaceuticals Inc. news events
Weekly update
A roundup of the hottest topics
EPRX
News
- Analysts See More Than 77% Upside for Eupraxia Pharmaceuticals (EPRX), Here's Why [Yahoo! Finance]Yahoo! Finance
- Eupraxia Pharmaceuticals (NASDAQ:EPRX) was downgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=EPRX&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">WalMarketBeat
- Individual investors account for 43% of Eupraxia Pharmaceuticals Inc.'s (TSE:EPRX) ownership, while institutions account for 26% [Yahoo! Finance]Yahoo! Finance
- Eupraxia Pharmaceuticals (NASDAQ:EPRX) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=EPRX&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall MarketBeat
- Eupraxia Pharmaceuticals Reports Third Quarter 2025 Financial Results [Canadian Business Journal (Canada)]Canadian Business Journal
EPRX
Sec Filings
- 11/14/25 - Form SCHEDULE
- 11/14/25 - Form SCHEDULE
- 11/13/25 - Form SCHEDULE
- EPRX's page on the SEC website